Jordyn Sava


Pembrolizumab Plus Lenvatinib Elicits Positive Clinical Activity in Recurrent Pleural Mesothelioma

August 7th 2022

The combination of pembrolizumab and lenvatinib generated promising clinical activity with a manageable safety profile in pretreated patients with malignant pleural mesothelioma.

Larotrectinib Exhibits Sustained Efficacy and Favorable Safety in TRK Fusion Lung Cancer

June 6th 2022

Rapid onset and sustained responses translating to extended survival and a favorable toxicity profile were seen with larotrectinib in patients with advanced lung cancer harboring NTRK gene fusions, including in those with central nervous system metastases, according to results from an expanded cohort.

Larotrectinib Shows Continued Tumor-Agnostic Efficacy in Pediatric TRK Fusion+ Cancer

June 6th 2022

Pediatric patients with non–central nervous system, TRK fusion–positive cancers who were enrolled to the phase 1/2 SCOUT and phase 2 NAVIGATE trials and received larotrectinib continued to experience rapid and durable tumor-agnostic efficacy and prolonged survival.

Larotrectinib Shows Sustained Efficacy, Safety Benefit in CNS TRK Fusion Cancer

June 5th 2022

Treatment with larotrectinib elicited robust and durable responses, had a favorable safety profile, and sustained survival benefit in patients with central nervous system TRK fusion cancers.

Addition of Ivosidenib to Azacitidine Improves Outcomes in Newly Diagnosed IDH1-Mutant AML

June 4th 2022

The combination of ivosidenib and azacitidine elicited a clinically meaningful benefit across end points compared with azacitidine alone among patients with newly diagnosed IDH1-mutant acute myeloid leukemia who were ineligible for intensive induction chemotherapy.

Positive Harm-Benefit Data Found in PSA Screening for Black Patients With Prostate Cancer

May 15th 2022

Complementary approaches to quantifying overdiagnosis generated a more beneficial harm-benefit tradeoff of prostate-specific antigen screening, compared with previous estimates that used shorter follow-up from the introduction of screening.

Up-Front Avelumab Maintenance Improves OS in Urothelial Carcinoma

May 14th 2022

Avelumab plus best supportive care produced a benefit in overall survival in patients with advanced urothelial carcinoma that had not progressed with first-line platinum-based chemotherapy.

Nivolumab Plus Chemotherapy Improves Event-Free Survival in Resectable NSCLC

April 11th 2022

The combination of nivolumab plus platinum-doublet chemotherapy led to a significant improvement in event-free survival compared with chemotherapy alone as neoadjuvant treatment in patients with resectable non–small cell lung cancer, according to findings from the phase 3 CheckMate 816 trial.

GD2-Directed CAR T-Cell Therapy Elicits Durable Benefit in H3K27M-Mutated Diffuse Intrinsic Pontine Gliomas

April 10th 2022

GD2-directed CAR T-cell therapy demonstrated prolonged periods of radiographic and clinical improvement in pediatric and young adult patients with H3K27M-mutated diffuse intrinsic pontine gliomas and spinal diffuse midline gliomas.

Elacestrant Significantly Improves PFS Over SOC in Advanced ER+ Metastatic Breast Cancer

March 5th 2022

Elacestrant was found to result in a statistically significant and clinically meaningful improvement in progression-free survival over standard-of-care treatment in patients with estrogen receptor–positive, HER2-negative metastatic breast cancer who previously received CDK4/6 inhibitors.